alpha-aminopyridine has been researched along with ceritinib in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Ichinose, Y; Seto, T; Takenoyama, M; Toyokawa, G | 1 |
| Bergqvist, S; Brooun, A; Burke, BJ; Dardaei, L; Deng, YL; Engelman, JA; Frias, RL; Friboulet, L; Gainor, JF; Getz, G; Iafrate, AJ; James, LP; Johnson, TW; Katayama, R; Le, L; Leshchiner, I; Liu, W; Logan, J; McTigue, M; Schultz, KR; Shaw, AT; Smeal, T; Timofeevski, S | 1 |
| Liu, D; Savooji, J; Wu, J | 1 |
| André, F; Auger, N; Besse, B; Facchinetti, F; Farace, F; Friboulet, L; Kuo, MS; Lacroix, L; Loriot, Y; Mahjoubi, L; Planchard, D; Remon, J; Scoazec, JY; Soria, JC | 1 |
| Benes, CH; Channick, C; Chin, E; Dagogo-Jack, I; Dardaei, L; Dias-Santagata, D; DiCecca, RH; Digumarthy, S; Engelman, JA; Friboulet, L; Gadgeel, S; Gainor, JF; Getz, G; Heist, RS; Huynh, T; Iafrate, AJ; Katayama, R; Keyes, C; Le, LP; Lee, D; Lennerz, J; Leshchiner, I; Lockerman, E; Logan, J; Mino-Kenudson, M; Muniappan, A; Parks, M; Ritterhouse, LL; Schultz, K; Sequist, LV; Shaw, AT; Singh, M; Yoda, S | 1 |
| Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M | 1 |
| Chow, LQM; Crino, L; De Pas, T; Felip, E; Mok, TSK; Salgia, R; Tan, DSW | 1 |
| Ma, MJ; Mekhail, TM; Parker, JV; Yuan, C | 1 |
| Hayashi, S; Hibino, Y; Kitada, M; Minami, Y; Miyokawa, N; Ohsaki, Y; Okumura, S; Sado, M; Sasaki, T; Yoshida, R | 1 |
| Araki, M; Fujita, N; Horiike, A; Ishikawa, T; Kanada, R; Katayama, R; Koike, S; Ma, B; Maemondo, M; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sakashita, T; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
| Buffoni, L; Pellerino, A; Rudà, R; Soffietti, R | 1 |
| Fujita, N; Horiike, A; Katayama, R; Kitazono, S; Koike, S; Nishikawa, S; Nishio, M; Ohyanagi, F; Tambo, Y; Tsukahara, M; Uchibori, K; Yanagitani, N; Yoshizawa, T | 1 |
| de Bruijn, P; Dingemans, AC; Koolen, SLW; Mathijssen, RHJ; Veerman, GDM | 1 |
| Dayang, EZ; Kuiper, T; Luxen, M; Molema, G; Moser, J; Rangarajan, S; van Meurs, M; Yan, R | 1 |
| Chen, P; Chen, Z; Li, J; Qian, J; Wang, C; Yue, D; Zhang, B; Zhang, H; Zhang, L | 1 |
| Li, H; Sun, Y; Wang, J; Xu, X | 1 |
| Chiang, CL; Chiang, TS; Chiu, CH; Chung, HP; Hung, JY; Ku, WH; Lee, KY; Lee, MH; Lin, CB; Lin, YT; Shih, JY; Su, J; Su, WC; Tseng, YH; Wei, YF; Wu, SY | 1 |
| Abdelhady, A; Ardizzoni, A; Barlesi, F; Ch Yang, J; Chen, X; DiDominick, S; Felip, E; Hyoung Kang, J; Navarro, A; Santoro, A; Simonelli, M; Stammberger, U; Su, WC | 1 |
| Liu, Q; Luo, X; Peng, L; Zeng, X; Zhou, Z | 1 |
4 review(s) available for alpha-aminopyridine and ceritinib
| Article | Year |
|---|---|
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Brain; Brain Neoplasms; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2015 |
Second- and third-generation ALK inhibitors for non-small cell lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Kaplan-Meier Estimate; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones | 2017 |
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2017 |
3 trial(s) available for alpha-aminopyridine and ceritinib
| Article | Year |
|---|---|
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Female; Humans; Lactams; Lactams, Macrocyclic; Liver Failure; Liver Neoplasms; Lung Neoplasms; Middle Aged; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2022 |
12 other study(ies) available for alpha-aminopyridine and ceritinib
| Article | Year |
|---|---|
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
Topics: Adolescent; Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Myofibroblasts; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sarcoma; Sulfones | 2017 |
Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Mice; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; src-Family Kinases; Sulfones; Xenograft Model Antitumor Assays | 2017 |
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Dynamics Simulation; Mutation, Missense; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Software; Sulfones | 2019 |
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Spinal Cord Neoplasms; Sulfones; Treatment Outcome | 2019 |
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Asian People; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recombinant Proteins; Sulfones | 2020 |
To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.
Topics: Aminopyridines; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Indoles; Lactams; Lactams, Macrocyclic; Pyrazoles; Pyrimidines; Quinazolinones; Reproducibility of Results; Sulfones; Tandem Mass Spectrometry | 2021 |
Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) identified via kinome profile analysis attenuates lipopolysaccharide-induced endothelial inflammatory activation.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Anti-Inflammatory Agents; Axl Receptor Tyrosine Kinase; Focal Adhesion Kinase 1; Gene Expression Profiling; HL-60 Cells; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Lipopolysaccharides; Protein Array Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridones; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfones; Time Factors; Transcriptome | 2021 |
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Immune Checkpoint Inhibitors; Lactams; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Nivolumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Sulfones; Time Factors; Treatment Outcome; Tumor Microenvironment | 2021 |
[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors
and Chemotherapy].
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Crizotinib; Female; Humans; Lactams; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Serine Endopeptidases; Sulfones | 2021 |
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; Sulfones; Taiwan; Treatment Outcome | 2021 |
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Crizotinib; Humans; Lactams; Lung Neoplasms; Network Meta-Analysis; Organophosphorus Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Sulfones | 2022 |